Skip to main content

Advertisement

SpringerLink
Log in

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

  • Review Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment for hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes, including a wide range of rheumatologic disorders. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropic effects of statins in rheumatologic disorders and emphasizes the importance of randomized, placebo-controlled trials to further elucidate this interesting phenomenon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pignone M, Phillips C, Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 321:983–985

    Article  PubMed  CAS  Google Scholar 

  2. Tonkin A, Aylward P, Colquhoun D et al. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 339(19):1349–1357

    Google Scholar 

  3. Endres M (2005) Statins and stroke. J Cereb Blood Flow Metab 25(9):1093–1110

    Article  PubMed  CAS  Google Scholar 

  4. Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86(1):5–18

    Article  PubMed  Google Scholar 

  5. Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM (2010) Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway. Cardiovasc Ther 28(1):8–14

    Article  PubMed  CAS  Google Scholar 

  6. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S (2005) Pleiotropic effects of statins. Indian J Pharmacol 37(2):77–85

    Article  CAS  Google Scholar 

  7. Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Müller GA (2009) Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 38(4):235–239

    Article  PubMed  CAS  Google Scholar 

  8. Lazzerini PE, Lorenzini S, Selvi E et al. (2007) Simvastatin inhibits cytokine production and nuclear factor-k B activation in interleukin 1-beta stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 25(5):696–700

    Google Scholar 

  9. Xu H, Liu P, Liang L et al (2006) RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54(11):3441–3451

    Article  PubMed  CAS  Google Scholar 

  10. Connor AM, Berger S, Narendran A, Keystone EC (2006) Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther 8(4):R94

    Article  PubMed  Google Scholar 

  11. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54(2):579–586

    Article  PubMed  CAS  Google Scholar 

  12. Yokota K, Miyoshi F, Miyazaki T et al (2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35(2):193–200

    PubMed  CAS  Google Scholar 

  13. Tikiz C, Utuk O, Pirildar T et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol 32(11):2095–2101

    PubMed  CAS  Google Scholar 

  14. Haruna Y, Morita Y, Yada T, Satoh M, Fox DA, Kashihara N (2007) Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum 56(6):1827–1835

    Article  PubMed  CAS  Google Scholar 

  15. Kinderlerer AR, Steinberg R, Johns M et al (2006) Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther 8(4):R130

    Article  PubMed  Google Scholar 

  16. Paumelle R, Blanquart C, Briand O et al (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98(3):361–369

    Article  PubMed  CAS  Google Scholar 

  17. Lin H, Xiao Y, Chen G et al. (2010) HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Rheumatol Int. 15 May 2010. (in press)

  18. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7(6):687–692

    Article  PubMed  CAS  Google Scholar 

  19. McCarey DW, McInnes IB, Madhok R et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363(9426):2015–2021

    Article  PubMed  CAS  Google Scholar 

  20. Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA (2009) Shirinsky versus changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 38(1):23–27

    Article  PubMed  CAS  Google Scholar 

  21. Mäki-Petäjä KM, Booth AD, Hall FC et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50(9):852–858

    Article  PubMed  Google Scholar 

  22. Okamoto H, Koizumi K, Kamitsuji S et al (2007) Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 34(5):964–968

    PubMed  CAS  Google Scholar 

  23. Bansback N, Ara R, Ward S, Anis A, Choi HK (2009) Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 27(1):25–37

    Article  PubMed  Google Scholar 

  24. Chodick G, Amital H, Shalem Y et al (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7(9):e1000336

    Article  PubMed  Google Scholar 

  25. Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68(4):546–551

    Article  PubMed  CAS  Google Scholar 

  26. Orozco P (2004) Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol 19(12):1105–1112

    Article  PubMed  CAS  Google Scholar 

  27. Hanayama R, Shimizu H, Nakagami H et al (2009) Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med 23(5):581–588

    PubMed  CAS  Google Scholar 

  28. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 123(8):1733–1740

    Article  PubMed  CAS  Google Scholar 

  29. Staal A, Frith JC, French MH et al (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18(1):88–96

    Article  PubMed  CAS  Google Scholar 

  30. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30(3):191–199

    Article  PubMed  CAS  Google Scholar 

  31. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N (2004) Induction of osteoblast differentiation indices by statins in MC3T3–E1 cells. J Cell Biochem 92(3):458–471

    Article  PubMed  CAS  Google Scholar 

  32. Li X, Cui Q, Kao C, Wang GJ, Balian G (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33(4):652–659

    Google Scholar 

  33. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86(9):4556–4559

    Article  PubMed  CAS  Google Scholar 

  34. Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K (2009) Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 63(3):261–267

    Article  PubMed  CAS  Google Scholar 

  35. Du Z, Chen J, Yan F, Xiao Y (2009) Effects of simvastatin on bone healing around titanium implants in osteoporotic rats. Clin Oral Implants Res 20(2):145–150

    Article  PubMed  Google Scholar 

  36. Wang JW, Xu SW, Yang DS, Lv RK (2007) Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int 18(12):1641–1650

    Article  PubMed  Google Scholar 

  37. Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16(8):990–998

    Article  PubMed  CAS  Google Scholar 

  38. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40(6):1581–1587

    Article  PubMed  CAS  Google Scholar 

  39. Yue J, Zhang X, Dong B, Yang M (2010) Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 17(5):1071–1079

    Article  PubMed  Google Scholar 

  40. Bauer DC, Mundy GR, Jamal SA et al (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164(2):146–152

    Article  PubMed  CAS  Google Scholar 

  41. Pérez-Castrillón JL, Vega G, Abad L et al (2008) Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. Ann Nutr Metab 53(2):117–121

    Article  PubMed  Google Scholar 

  42. Pérez-Castrillón JL, Vega G, Abad L et al. (2009) Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene. Endocr J 56(2):221–225

    Google Scholar 

  43. Bakhireva LN, Shainline MR, Carter S et al (2010) Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherapy 30(9):879–887

    Article  PubMed  CAS  Google Scholar 

  44. Tanriverdi HA, Barut A, Sarikaya S (2005) Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 120(1):63–68

    Article  PubMed  CAS  Google Scholar 

  45. De Leo V, Morgante G, la Marca A, Lanzetta D, Cobellis L, Petraglia F (2003) Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol Endocrinol 17(4):329–332

    PubMed  Google Scholar 

  46. Amuro H, Ito T, Miyamoto R et al (2010) Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 62(7):2073–2085

    PubMed  CAS  Google Scholar 

  47. Ferreira GA, Teixeira AL, Sato EI (2010) Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19(8):927–934

    Article  PubMed  CAS  Google Scholar 

  48. Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177(10):7416–7422

    PubMed  CAS  Google Scholar 

  49. Shimazu H, Kinoshita K, Hino S et al (2010) Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol 136(2):188–196

    Article  PubMed  CAS  Google Scholar 

  50. Woo JM, Lin Z, Navab M et al (2010) Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 12(3):R93

    Article  PubMed  Google Scholar 

  51. Aprahamian T, Bonegio R, Rizzo J et al (2006) Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 177(5):3028–3034

    PubMed  CAS  Google Scholar 

  52. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173(12):7641–7646

    PubMed  CAS  Google Scholar 

  53. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS (2010) Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis 70(5):760–765

    Google Scholar 

  54. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46(10):1560–1565

    Article  CAS  Google Scholar 

  55. Belmont HM, Lydon E (2005) Avascular necrosis prevention with lipitor in lupus erythematosus. Lupus 14(10):869–870

    Article  PubMed  CAS  Google Scholar 

  56. Del Papa N, Cortiana M, Vitali C et al (2008) Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 35(7):1323–1328

    PubMed  CAS  Google Scholar 

  57. Abou-Raya A, Abou-Raya S, Helmii M (2007) Statins as immunomodulators in systemic sclerosis. Ann NY Acad Sci. 1110:670–680

    Article  PubMed  CAS  Google Scholar 

  58. Kuwana M (2006) Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 18(6):594–600

    Article  PubMed  CAS  Google Scholar 

  59. Louneva N, Huaman G, Fertala J, Jiménez SA (2006) Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 54(4):1298–1308

    Article  PubMed  CAS  Google Scholar 

  60. Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35(9):1801–1808

    PubMed  CAS  Google Scholar 

  61. Kuwana M, Okazaki Y, Kaburaki J (2009) Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 19(5):530–535

    Article  PubMed  CAS  Google Scholar 

  62. Simopoulou T, Malizos KN, Poultsides L, Tsezou A (2010) Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 28(1):110–115

    PubMed  CAS  Google Scholar 

  63. Sverdrup FM, Yates MP, Vickery LE et al (2010) Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthritis Cartilage 18(7):948–955

    Article  PubMed  Google Scholar 

  64. Litinsky I, Golan I, Yaron M, Yaron I, Caspi D, Elkayam O (2009) Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J. 3:35–40

    Article  PubMed  CAS  Google Scholar 

  65. Lazzerini PE, Capecchi PL, Nerucci F et al (2004) Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 63(7):867–869

    Article  PubMed  CAS  Google Scholar 

  66. Rabinowitz JL, Gregg JR, Nixon JE, Schumacher HR (1979) Lipid composition of the tissues of the human knee joints. I—Observations in normal joints (articular cartilage, meniscus, ligaments, synovial fluid, synovium, intra-articular fat pad and bone marrow). Clin Orthop Relat Res (143):260–265

  67. Pritchett JW (2007) Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin Orthop Relat Res. 456:233–237

    PubMed  Google Scholar 

  68. Akasaki Y, Matsuda S, Nakayama K, Fukagawa S, Miura H, Iwamoto Y (2009) Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 17(2):235–243

    Article  PubMed  CAS  Google Scholar 

  69. Akasaki Y, Matsuda S, Iwamoto Y (2009) Progress of research in osteoarthritis. The anti-inflammatory effects of intra-articular injected statin on experimental osteoarthritis. Clin Calcium 19(11):1653–1662

    Google Scholar 

  70. López-Pedrera C, Ruiz-Limón P, Aguirre MA et al. (2010) Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 70(4):675–682

    Google Scholar 

  71. Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS (2009) Statins for the treatment of antiphospholipid syndrome? Ann N Y Acad Sci 1173:736–745

    Article  PubMed  CAS  Google Scholar 

  72. Meroni PL, Raschi E, Testoni C et al (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44(12):2870–2878

    Article  PubMed  CAS  Google Scholar 

  73. Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G (2008) Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 118(10):3453–3461

    PubMed  CAS  Google Scholar 

  74. Ferrara DE, Liu X, Espinola RG et al (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48(11):3272–3279

    Article  PubMed  CAS  Google Scholar 

  75. Vasiuk IuA, Perlamutrov IuN, Shkol’nik MN, Shkol’nik EL (2010) Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia. 50(3):37–46

    Google Scholar 

  76. Naseri M, Hadipour A, Sepaskhah M, Namazi MR (2010) The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 19(1):58–61

    PubMed  CAS  Google Scholar 

  77. Hamaoka A, Hamaoka K, Yahata T et al (2010) Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56(2):245–253

    Article  PubMed  Google Scholar 

  78. Huang SM, Weng KP, Chang JS et al (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after kawasaki disease: a pilot study. Circ J 72(10):1583–1587

    Article  PubMed  CAS  Google Scholar 

  79. van Denderen JC, Peters MJ, van Halm VP et al (2006) Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 65(5):695–696

    Article  PubMed  Google Scholar 

  80. Inanc MT, Kalay N, Heyit T et al (2010) Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet’s disease. Echocardiography 27(8):997–1003

    Article  PubMed  Google Scholar 

  81. Hashimoto T, Toya Y, Kihara M et al (2008) Behçet’s disease complicated by IgA nephropathy with nephrotic syndrome. Clin Exp Nephrol 12(3):224–227

    Article  PubMed  Google Scholar 

  82. ten Cate R, Nibbering PH, Bredius RG (2004) Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins. Rheumatology (Oxford) 43(7):934–935

    Article  CAS  Google Scholar 

  83. Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116(6):408–416

    Article  PubMed  CAS  Google Scholar 

  84. Sailler L, Pereira C, Bagheri A et al (2008) Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 67(5):614–619

    Article  PubMed  CAS  Google Scholar 

  85. Sen D, Rosenstein ED, Kramer N (2010) ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis 13(3):e29–e31

    Article  PubMed  Google Scholar 

  86. Haroon M, Devlin J (2008) A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol 27(Suppl 2):S75–S77

    Article  PubMed  Google Scholar 

  87. Noel B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21(1):17–24

    Article  PubMed  CAS  Google Scholar 

  88. Goëb V, Guillemant N, Vittecoq O, Le Loët X (2004) Cerivastatin-induced polymyalgia rheumatica-like illness. Clin Rheumatol 23(2):179

    Article  PubMed  Google Scholar 

  89. Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35(11):732–736

    Article  PubMed  Google Scholar 

  90. Adams AE, Bobrove AM, Gilliam AC (2010) Statins and “chameleon-like” cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg 14(5):207–211

    PubMed  Google Scholar 

  91. Adams AE, Bobrove AM, Gilliam AC (2010) Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis 70(5):877–878

    Google Scholar 

  92. Aronow C, Diamond B. A double blind, placebo controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. National Institute of Allergy and Infectious Diseases. Clinialtrials gov NCT00302952

  93. Ming Li EK. Effects of HMG-coA reductase inhibitor on progression of carotid intima-media thickness and arterial stiffness in rheumatoid arthritis. The Chinese University of Hong Kong. Clinicaltrial gov NCT00555230

  94. Ansell BJ. Effects of atorvastatin on disease activity and HDL cholesterol anti-inflammatory properties in patients with rheumatoid arthritis. The University of California, Los Angeles. Clinicatrial gov NCT00356473

  95. Pfizer, Inc. Phase 2 study of the effects of open-label CP-690,550 and double-blind atorvastatin on lipids in patients with active rheumatoid arthritis. Clinicaltrial gov NCT01059864

  96. Abdou NI. Statins and Lupus: effects of statins on clinical lupus parameters, serological markers and toll-like receptors. St. Luke’s Hospital. Clinicaltrial gov NCT00519363

  97. Lai NS. An open labeled pilot study of atorvastatin in systemic lupus erythematosus. Buddhist Dalin Chi Tzu General Hospital. Clinicaltrial gov NCT00432354

  98. Schanberg LE. A multicenter, randomized, double-blind, placebo-controlled study to test the safety and efficacy of lipitor (atorvastatin) in reducing the progression of carotid IMT in early childhood SLE. Duke University. Clinicaltrial gov NCT00065806

  99. Belmont HM. Atorvastatin to prevent avascular necrosis of bone in steroid treated exacerbated systemic lupus erythematosus. New York University. Clinicaltrial gov NCT00412841

  100. Erkan D, Pierangeli S. Effects of fluvastatin on proinflammatory and prothrombotic markers in antiphospholipid syndrome patients. Hospital for Special Surgery. Clinicaltrial gov NCT00674297

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Cardiology, Mount Sinai Heart Institute, Columbia University, 4300 Alton Road, Miami Beach, FL, 33140, USA

    Christos G. Mihos & Orlando Santana

  2. Department of Internal Medicine, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL, 33140, USA

    Rosa T. Artola

Authors
  1. Christos G. Mihos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosa T. Artola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orlando Santana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orlando Santana.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mihos, C.G., Artola, R.T. & Santana, O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 32, 287–294 (2012). https://doi.org/10.1007/s00296-011-2008-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2008-6

Keywords

Search

Navigation